SVEP1 and hepatocellular carcinoma: Our group first identified abnormal SVEP1 expression alongside four other genes as high-heterogeneity prognostic biomarkers for HCC in 2022, based on large-scale single-cell sequencing of samples from patients with varied recurrence characteristics [19].